Play Video This will play a video - Video thumbnail

Personalized CRT Study

Evaluating real-world outcomes for heart failure patients receiving cardiac resynchronization therapy (CRT).

Study Overview

The Personalized CRT study is part of the Medtronic Product Surveillance Registry. It is a prospective, real-world, observational study with the objective to understand CRT response and evaluate new CRT technologies to optimize heart failure treatment. These include product performance, patient safety, and clinical outcomes.

The study's design provides timely access to a robust data set. Currently, there are over 12,000 patients enrolled at 300 centers in 16 countries. We have been enrolling patients since 2001 and it is ongoing. 

View Video

Study Design

Infographic showing the different steps and components of the Personalized CRT Study

Key Results

Improved Survival with Dynamic Optimization of CRT Pacing Using the AdaptivCRT™ Algorithm: Analysis of Real-world Patient Data

Analysis Design

A total of 1,814 patients who had no reported long-standing AF history were included in the analysis. Frailty survival models were used to evaluate the potential survival benefit of the algorithm, adjusting for patient heterogeneity and center variability. 

Graph showing a 29% relative reduction in all-cause mortality with AdaptivCRT

Conclusion

Patients who received AdaptivCRT were associated with a 29% relative reduction in
all-cause mortality versus conventional CRT (after adjusting for other potential risk factors including age, gender, LVEF, NYHA class, QRS duration, AF, CAD, hypertension, AV block, and LBBB).*1

Learn More about AdaptivCRT
*

Studies have shown that the most common adverse events associated with CRT therapy are lead dislodgement, diaphragmatic stimulation, coronary-sinus dissection, pocket hematoma, pneumothorax, and device-related infection.

Reference

1

Singh JP, Cha YM, Lunati M, et al. Real-world behavior of CRT pacing using the AdaptivCRT algorithm on patient outcomes: Effect on mortality and atrial fibrillation incidence. J Cardiovasc Electrophysiol. April 2020;31(4):825-833.